The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of polybromo-associated baf (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).
 
Sarah Abou Alaiwi
No Relationships to Disclose
 
Amin Nassar
No Relationships to Disclose
 
Ziad El Bakouny
No Relationships to Disclose
 
Jacob E Berchuck
No Relationships to Disclose
 
Pier Nuzzo
No Relationships to Disclose
 
Ronan Flippot
Travel, Accommodations, Expenses - Pfizer
 
Abdallah Flaifel
No Relationships to Disclose
 
John A. Steinharter
No Relationships to Disclose
 
Sylvan Baca
No Relationships to Disclose
 
Claire Margolis
No Relationships to Disclose
 
Natalie Vokes
No Relationships to Disclose
 
Heng Du
No Relationships to Disclose
 
Sachet A Shukla
No Relationships to Disclose
 
David A. Braun
No Relationships to Disclose
 
Sabina Signoretti
Consulting or Advisory Role - AACR; AstraZeneca/MedImmune; Merck; NCI
Research Funding - AstraZeneca (Inst); Exelixis (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for CDX2 antibody from Biogenex Laboratories, Inc.
 
Guru Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Agensys; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Genentech; Janssen; Merck; Novartis; Sanofi
Speakers' Bureau - Clinical Care Options/NCCN; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Janssen (Inst); Merck (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Boehringer Ingelheim; Bristol-Myers Squibb
 
David J. Kwiatkowski
Consulting or Advisory Role - Genentech/Roche; Novartis
Research Funding - AADi; Genentech/Roche; Revolution Medicines
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - Genome Medical; Microsoft; Syapse; Tango Therapeutics
Consulting or Advisory Role - Dynamo Therapeutics; Forest Laboratories/Actavis; Genome Medical; Illumina; InVitae; Novartis; Roche; Syapse; Takeda; Tango Therapeutics; Third Rock Ventures
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - Dana Farber Cancer Hospital; Kidney Cancer Association; NCCN
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel